Pyxis Oncology

United States
Panora, Iowa, United States, 02118

Company profile

Pyxis Oncology company profile

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2019-01-01, Year

Headquarters

Postal code
02118
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
3
Total equity funding
$224M
Last funding
Post IPO Equity / $50M / 2024-02-27
Last equity funding
Post IPO Equity / $50M
Investors
23
Lead investors
3
Founders
3
Articles
117
Exited on
2021-10-08

Founders and investors

Founders

David SteinbergJohn L. FlavinShaan Gandhi

Lead investors

Arix BioscienceLeaps by BayerRTW Investments

Investors

Blue OwlCormorant Asset ManagementJanus Henderson InvestorsRA Capital ManagementRTW Investments